Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma

4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: To contextualize the effectiveness of tisagenlecleucel versus real-world standard of care (SoC) in relapsed/refractory follicular lymphoma. Materials & methods: A retrospective indirect matched comparison study using data from the phase II ELARA trial and the US Flatiron Health Research Database. Results: Complete response rate was 69.1 versus 17.7% and the overall response rate was 85.6 versus 58.1% in tisagenlecleucel versus SoC, post weighting by odds. For overall survival, an estimated reduction in the risk of death was observed in favor of tisagenlecleucel over SoC. The hazard ratio for progression-free survival was 0.45 (95% CI: 0.26, 0.88), and for time-to-next treatment was 0.34 (95% CI: 0.15, 0.78) with tisagenlecleucel versus SoC. Conclusion: A consistent trend toward improved efficacy end points was observed in favor of tisagenlecleucel versus SoC.

Cite

CITATION STYLE

APA

Hao, Y., Hsu, W. C., Parzynski, C. S., Degtyarev, E., Hampson, L. V., Masood, A., & Wu, W. H. (2023). Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma. Journal of Comparative Effectiveness Research, 12(7). https://doi.org/10.57264/cer-2022-0173

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free